Sponsor link (press release) https://cdmrp.army.mil/pubs/press/2022/22mbrppreann

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. 

Clinical Translational Research Award – Preproposal due June 27, 2022

Investigators at all academic levels (or equivalent)

• Intended to support human research projects that are likely to have a major impact on patient care by applying promising and well-founded research findings to the care of the burn-injured patient, particularly at the point of injury, or during the acute phase of injury.
• Impact is a key component of this award mechanism and should be clearly described.
• The proposed study must include clinical research, and may include initial proof-of-concept trials, studies involving use of human anatomical substances, observational studies, and/or involve some retrospective data analysis.
• Large randomized clinical trials are discouraged.
• Preliminary data is required.
• Animal research is not allowed.
• Pre-application submission is required; application submission is by invitation only.
• The maximum allowable funding for the entire period of performance is $2.21 million for total costs (direct plus indirect costs)
• Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

Technology/Therapeutic Development Award – Preproposal due June 27, 2022

Investigators at all academic levels (or equivalent)

• Intended to support the translation of promising preclinical findings into products for clinical applications.
• Product-oriented (e.g., device, drug, clinical guidelines). The product(s) to be developed may be a tangible item such as a pharmacologic agent (drugs or biologics) or device, or a knowledge-based product.
• Proof of concept demonstrating the potential utility of the proposed product, or a prototype/preliminary version of the proposed product, should already be established. 
• Preliminary data is required.
• Clinical trials are not allowed.
• Pre-application submission is required; application submission is by invitation only.
• The maximum allowable funding for the entire period of performance is $2.21 million for total costs (direct plus indirect costs)
• Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.
• The maximum period of performance is 4 years.